the satiety question that gets asked weekly, answered properly
the satiety question that gets asked weekly, answered properly, and I am aware this is a minority view on this board. Why this compound is not simply another agonist, which is how it gets described everywhere else. Amylin is co-secreted with insulin and signals satiety through its own receptor complexes. It is a…
Retitled to distinguish the combination arm from the monotherapy arm, which the original ran together.
Disagree — you are quoting a combination arm as though it were monotherapy. Those are different results.
Agreed that the monotherapy numbers look modest out of context and that the context is the whole story.
Not convinced. Amylin signalling is not a GLP-1 pathway and the mechanism you are proposing conflates them.
Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.
nothing here is approved as a standalone product and research material is not for human use
nothing here is approved as a standalone product and research material is not for human use
This is the distinction that keeps this board honest — different axis, not a stronger version of the same one.
nothing containing this is approved as a standalone product
Do you have the publication or a summary of it?
The engineering problem was duration: native amylin is short-acting and aggregation-prone. A long-acting analogue suitable for weekly administration is what makes the combination clinically interesting.
phase 3 data will change most of what gets said here